(CON) Concentra Holdings Parent - Overview
Sector: Healthcare | Industry: Medical Care Facilities | Exchange: NYSE (USA) | Market Cap: 3.240m USD | Total Return: 19.8% in 12m
Avg Turnover: 16.8M
Qual. Beats: 1
Rev. Trend: 94.6%
Qual. Beats: 1
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Concentra Group Holdings Parent, Inc. (CON) is a specialized provider of occupational health services in the United States. Founded in 1979 and headquartered in Addison, Texas, the company operates through three primary segments: physical health centers, onsite clinics at employer locations, and ancillary business services. Its core offerings include workers compensation injury care, employer-mandated drug and alcohol screenings, physical examinations, and preventive primary care.
The company utilizes a vertically integrated business model that incorporates a proprietary telemedicine platform, Concentra Telemed, and an internal pharmacy for medication distribution. This structure addresses the specific regulatory requirements of the occupational health sector, where service providers must navigate complex state-level workers compensation laws and federal Department of Transportation compliance standards. Unlike general urgent care, the occupational health model relies heavily on business-to-business contracts and recurring compliance-driven demand.
For a more detailed analysis of the companys competitive positioning and valuation, consider reviewing the comprehensive data on ValueRay. This summary provides a baseline for understanding Concentra’s role as a dominant intermediary between employers, employees, and insurance carriers within the healthcare services infrastructure.
- Growth in United States employment levels drives demand for occupational health services
- Workers compensation patient volume and reimbursement rates dictate core revenue performance
- Labor cost inflation and medical professional shortages impact operational profit margins
- Expansion of onsite clinics and telemedicine adoption improves long-term capital efficiency
- Federal workplace safety regulations and drug testing mandates sustain compliance service demand
| Net Income: 178.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA 3.60 > 1.0 |
| NWC/Revenue: 3.73% < 20% (prev 1.61%; Δ 2.12% < -1%) |
| CFO/TA 0.10 > 3% & CFO 288.7m > Net Income 178.0m |
| Net Debt (2.61b) to EBITDA (429.4m): 6.07 < 3 |
| Current Ratio: 1.26 > 1.5 & < 3 |
| Outstanding Shares: last quarter (128.2m) vs 12m ago 1.20% < -2% |
| Gross Margin: 27.79% > 18% (prev 0.29%; Δ 2.75k% > 0.5%) |
| Asset Turnover: 79.45% > 50% (prev 70.84%; Δ 8.62% > 0%) |
| Interest Coverage Ratio: 3.19 > 6 (EBITDA TTM 429.4m / Interest Expense TTM 109.9m) |
| A: 0.03 (Total Current Assets 404.2m - Total Current Liabilities 320.9m) / Total Assets 2.89b |
| B: 0.06 (Retained Earnings 186.8m / Total Assets 2.89b) |
| C: 0.12 (EBIT TTM 350.5m / Avg Total Assets 2.81b) |
| D: 0.08 (Book Value of Equity 186.8m / Total Liabilities 2.44b) |
| Altman-Z'' = 1.32 = BB |
| DSRI: 0.99 (Receivables 296.5m/258.1m, Revenue 2.23b/1.93b) |
| GMI: 1.04 (GM 27.79% / 28.94%) |
| AQI: 0.97 (AQ_t 0.61 / AQ_t-1 0.63) |
| SGI: 1.15 (Revenue 2.23b / 1.93b) |
| TATA: -0.04 (NI 178.0m - CFO 288.7m) / TA 2.89b) |
| Beneish M = -2.94 (Cap -4..+1) = A |
As of May 27, 2026, the stock is trading at USD 25.53 with a total of 628,270 shares traded.
Over the past week, the price has changed by -1.87%,
over one month by +12.89%,
over three months by +8.56% and
over the past year by +19.84%.
Concentra Holdings Parent has received a consensus analysts rating of 4.63. Therefore, it is recommended to buy CON.
- StrongBuy: 5
- Buy: 3
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 31.7 | 24.2% |
P/E Trailing = 18.2158
P/E Forward = 17.6991
P/S = 1.4515
P/B = 7.6287
Revenue TTM = 2.23b USD
EBIT TTM = 350.5m USD
EBITDA TTM = 429.4m USD
Long Term Debt = 1.56b USD (from longTermDebt, last quarter)
Short Term Debt = 98.9m USD (from shortTermDebt, last quarter)
Debt = 2.67b USD (from shortLongTermDebtTotal, last quarter) + Leases 546.5m
Net Debt = 2.61b USD (calculated: Debt 2.67b - CCE 61.7m)
Enterprise Value = 5.85b USD (3.24b + Debt 2.67b - CCE 61.7m)
Interest Coverage Ratio = 3.19 (Ebit TTM 350.5m / Interest Expense TTM 109.9m)
EV/FCF = 19.93x (Enterprise Value 5.85b / FCF TTM 293.4m)
FCF Yield = 5.02% (FCF TTM 293.4m / Enterprise Value 5.85b)
FCF Margin = 13.14% (FCF TTM 293.4m / Revenue TTM 2.23b)
Net Margin = 7.97% (Net Income TTM 178.0m / Revenue TTM 2.23b)
Gross Margin = 27.79% ((Revenue TTM 2.23b - Cost of Revenue TTM 1.61b) / Revenue TTM)
Gross Margin QoQ = 26.48% (prev 26.11%)
Tobins Q-Ratio = 2.02 (Enterprise Value 5.85b / Total Assets 2.89b)
Interest Expense / Debt = 4.12% (Interest Expense 109.9m / Debt 2.67b)
Taxrate = 24.88% (17.3m / 69.6m)
NOPAT = 263.3m (EBIT 350.5m * (1 - 24.88%))
Current Ratio = 1.26 (Total Current Assets 404.2m / Total Current Liabilities 320.9m)
Debt / Equity = 6.28 (Debt 2.67b / totalStockholderEquity, last quarter 424.7m)
Debt / EBITDA = 6.07 (Net Debt 2.61b / EBITDA 429.4m)
Debt / FCF = 8.89 (Net Debt 2.61b / FCF TTM 293.4m)
Total Stockholder Equity = 386.5m (last 4 quarters mean from totalStockholderEquity)
RoA = 6.34% (Net Income 178.0m / Total Assets 2.89b)
RoE = 46.05% (Net Income TTM 178.0m / Total Stockholder Equity 386.5m)
RoCE = 17.98% (EBIT 350.5m / Capital Employed (Equity 386.5m + L.T.Debt 1.56b))
RoIC = 10.10% (NOPAT 263.3m / Invested Capital 2.61b)
WACC = 6.16% (E(3.24b)/V(5.91b) * Re(8.69%) + D(2.67b)/V(5.91b) * Rd(4.12%) * (1-Tc(0.25)))
Discount Rate = 8.69% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 79.50 | Cagr: 0.55%
[DCF] Terminal Value 77.97% ; FCFF base≈247.6m ; Y1≈283.8m ; Y5≈417.7m
[DCF] Fair Price = 28.75 (EV 6.29b - Net Debt 2.61b = Equity 3.68b / Shares 128.0m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 4.0 | # QB: 1
Revenue Correlation: 94.62 | Revenue CAGR: 8.49% | SUE: 2.16 | # QB: 1
EPS current Quarter (2026-06-30): EPS=0.43 | Chg30d=-2.15% | Revisions=-20% | Analysts=7
EPS next Quarter (2026-09-30): EPS=0.42 | Chg30d=-3.91% | Revisions=+0% | Analysts=7
EPS current Year (2026-12-31): EPS=1.54 | Chg30d=+3.75% | Revisions=+43% | GrowthEPS=+12.3% | GrowthRev=+7.9%
EPS next Year (2027-12-31): EPS=1.73 | Chg30d=+3.75% | Revisions=+56% | GrowthEPS=+12.2% | GrowthRev=+5.8%
[Analyst] Revisions Ratio: +56%